Cognitive impairment in type 2 diabetes mellitus

Abstract

Mild cognitive impairment (MCI) and type 2 diabetes mellitus (DM2) are two common disabling states. Neurodegeneration can be a reason for insulin resistance, as well as a consequence of insulin resistance. So, vicious circle, resulting in progression of cognitive impairment, forms. The aim of this study was to estimate influence of ant dement drug rivastigmine on cognitive functioning and glycaemia in patients with MCI co morbid to DM2. 28 outpatients, aged 55–72 (m. – 9, f. – 19), were included to the pilot, openM label, nonMcomparative study, lasting 3 months. The initial dose of rivastigmine was 1,5 mg/d, with the consequent titration to 6 mg/d. The total score of MoCa scale statistically significantly increased from 21,5 ± 0,8 at D0 to 22,5 ± 1,0 at the end of the study. Glycaemia statistically significantly decreased from 10,2 ± 1,3 mmol/llat D0 to 9,4 ± 1,1mmol/l, from the 1st month of the study. 9 from 28 patients also decreased dosage and/or number of oral hypoglycemic drugs.